Getty Images Some lawmakers want to expand retirees' options for making charitable donations from their individual retirement accounts . Under current tax law, anyone who's at least age 70½ can make what's known as a qualified charitable distribution , or QCD, which is a direct transfer from an IRA to an eligible nonprofit. A new bipartisan Senate bill would also allow those IRA owners to direct Q...
Getty Images Some lawmakers want to expand retirees' options for making charitable donations from their individual retirement accounts . Under current tax law, anyone who's at least age 70½ can make what's known as a qualified charitable distribution , or QCD, which is a direct transfer from an IRA to an eligible nonprofit. A new bipartisan Senate bill would also allow those IRA owners to direct QCDs to donor-advised funds. A DAF is a charitable giving account managed by a public nonprofit. Donors get an up-front tax deduction for their contribution to the fund, and they can recommend donations to qualifying charities over time. The Senate measure, introduced March 3 as a companion to an existing House bill floated last year, would mean a change to the existing general requirement that QCDs go directly to charities. The Senate bill was referred to the Finance Committee, and the House measure is in the Ways and Means Committee. Read more CNBC personal finance coverage BlackRock CEO Fink: Trump accounts may be 'significant' wealth-building tool The uneven cost of tariffs: Why some households will pay more than others When it comes to private credit, 'some caution is reasonable,' advisor says 'War tax resistance' gains attention amid Iran conflict, but IRS penalties apply Average IRS tax refund is up 10.8%, new filing data shows Your tax refund could be smaller than expected this season. Here's why What may happen to Social Security benefits in six years if Congress doesn't act Trump officials task Treasury Department with student loan collection Harvard University tops this year's list of 'dream colleges': The Princeton Review 9% of ACA enrollees go uninsured after enhanced subsidies expire, poll finds The Fed keeps rates unchanged in March: What that means for you Many states' unemployment benefits fall far short of average wages: Analysis Iran war, oil price surge worsen K-shaped economy, say economists More than 576,000 student loan borrowers in repayment plan back...
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guarant...
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company’s existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were issued on September 12, 2025 (the “Existing Notes”), will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes other than with respect to the date of issuance and the issue price.
Antonio_Diaz/iStock via Getty Images Based in Tempe, AZ, and founded in 1997, Align Technology, Inc. ( ALGN ) is a leading manufacturer of orthodontic treatments globally. They sell clear aligners under the Invisalign and Vivera brands as well as iTero scanners, alongside its associated CAD software, Exocad. Invisalign, now a well-known if not household name, is “the #1 doctor recommended clear al...
Antonio_Diaz/iStock via Getty Images Based in Tempe, AZ, and founded in 1997, Align Technology, Inc. ( ALGN ) is a leading manufacturer of orthodontic treatments globally. They sell clear aligners under the Invisalign and Vivera brands as well as iTero scanners, alongside its associated CAD software, Exocad. Invisalign, now a well-known if not household name, is “the #1 doctor recommended clear aligner brand in the world”, based on a 2022 survey . Since launching in 1999, they have been used by 22.1 million people worldwide. The company has retained relationships with over 2 million orthodontists globally – almost 300,000 of which are presently operating and using Align’s products – which continues to sustain their leading market share and control of large parts of the supply chain. This includes the physicians who prescribe treatments after scanning patient’s teeth using Align’s own hardware and software, the supply of orthodontic solutions themselves, alongside the manufacturers that build the aligners for patient’s teeth. Alongside their strong brand and network of ongoing relationships with physicians, this provides them with a competitive advantage over their smaller competitors. That said, competitive pressured have increased, which has brought into question their moat based around barriers to entry for competitors. Seeking Alpha Shares have underperformed the S&P500 over the last decade, and particularly poorly since their peak in 2021, during the Covid bull run. However, since my last coverage (a “buy” rating) in August last year, shares have gained around 30%. I seemed to have called the bottom on the stock – or close to it – which is probably more luck than ability on my part, as I believed their fundamentals always pointed to a decent rebound. The questions were when and how low would the stock go? I would encourage readers to return to my first coverage as it provides something of a deep dive on the company and what I perceived at the time to be its long...
Newly opened museum in north London has archive of more than 100,000 items telling story of British youth subcultures Punk masks, Walkmans and Choppers: Museum of Youth Culture to open in London Continue reading...
Newly opened museum in north London has archive of more than 100,000 items telling story of British youth subcultures Punk masks, Walkmans and Choppers: Museum of Youth Culture to open in London Continue reading...
Jack Thorne’s blistering drama picks up the most nods, followed by Steven Knight’s boxing period drama A Thousand Blows and politically charged Star Wars spin-off Andor Bafta TV awards 2026 nominations: full list Adolescence, Jack Thorne’s groundbreaking drama about a teen accused of murder, has been nominated for the most 2026 TV Bafta awards. Reviewed by the Guardian as being “ the closest thing...
Jack Thorne’s blistering drama picks up the most nods, followed by Steven Knight’s boxing period drama A Thousand Blows and politically charged Star Wars spin-off Andor Bafta TV awards 2026 nominations: full list Adolescence, Jack Thorne’s groundbreaking drama about a teen accused of murder, has been nominated for the most 2026 TV Bafta awards. Reviewed by the Guardian as being “ the closest thing to TV perfection in decades ”, the Netflix psychological crime drama leads the pack with 11 nominations, including the first Bafta TV performance nominations for supporting actor and actress awards for four of its actors: Ashley Walters, Christine Tremarco, Erin Doherty and Owen Cooper. Continue reading...
格隆汇3月24日｜巴伦投资发文指出，每次A股一调整，量化准会被拎出来“背锅”，最近这轮地缘冲突引发的市场震荡也不例外。刚刚过去的周末里，已经有很多投资人po出某些热点股票的“A字”走势图，控诉量化的“罪行”。但话说回来，量化在美股活跃更久，为啥人家就没这么多恶名，更没听说把散户割得这么惨？究其原因，其实是两个市场的底层逻辑完全不一样。 其一，投资者结构不一样。量化赚的，本质是市场无效性的钱，是错误定价的钱。美股是机构主导的成熟市场，散户占比远低于A股，市场里全是专业机构的模型对杀，最终只能赚个平均收益，根本拿不到超额利润。而 A 股有海量的散户，多年来还是习惯于追涨杀跌，给量化提供了源源不断的收割对象，市场波动越大、投机越疯、交易越频繁，量化就赚得越爽。 其二，上市公司基本面不一样。美股为什么能走长牛？龙头公司盈利够硬，科股七巨头除特斯拉之外净利润都接近千亿美元级，而 A 股整个创业板2025年全年的净利润按一致预期才3000多亿人民币，还不到六巨头中任一家公司。像阿里、腾讯这些最优质的中国企业，大多没在A股上市；场内的公司稍微一炒，估值就没法看。这使得市场大部分时间被情绪和流动性主导，大家都在玩博傻游戏，价值投资始终难以扎根。 也有另一种观点：量化其实是在加速投资者的成熟。既然它赚的是错误定价的钱，那它本质上就是在淘汰那些只会乱投机的散户，倒逼所有参与者回归公司基本面，关心业绩和真实成长性，最终推动市场走向真正的价值投资。从这个角度来看，量化相当于市场的“牧羊犬”。但对于普通散户来说，等不起这个漫长的过程，更付不起这个昂贵的学费。当下最该思考的是，新型市场生态下，怎么不被量化收割。
(RTTNews) - UK stock market's benchmark FTSE 100 was up marginally a little past noon on Tuesday with stocks turning in a mixed performance in cautious trading amid conflicting reports on potential U.S.-Iran talks on ending the conflict.
(RTTNews) - UK stock market's benchmark FTSE 100 was up marginally a little past noon on Tuesday with stocks turning in a mixed performance in cautious trading amid conflicting reports on potential U.S.-Iran talks on ending the conflict.
LENZ Therapeutics press release ( LENZ ): Q4 GAAP EPS of -$1.16 misses by $0.26 . Revenue of $1.59M misses by $1.5M . Cash, cash equivalents and marketable securities were $292.3 million as of December 31, 2025, which is anticipated to fund operations to post-launch positive operating cash flow. More on LENZ Therapeutics Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health...
LENZ Therapeutics press release ( LENZ ): Q4 GAAP EPS of -$1.16 misses by $0.26 . Revenue of $1.59M misses by $1.5M . Cash, cash equivalents and marketable securities were $292.3 million as of December 31, 2025, which is anticipated to fund operations to post-launch positive operating cash flow. More on LENZ Therapeutics Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag Seeking Alpha’s Quant Rating on LENZ Therapeutics Historical earnings data for LENZ Therapeutics Financial information for LENZ Therapeutics
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. The performance was in line with expectations for the full year. The firm believes […]
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. The performance was in line with expectations for the full year. The firm believes […]
From World Cup preparations to Champions League complications, the issues facing football in the region It has been a little over three weeks since the United States and Israel attacked Iran and plunged the Middle East into war. Football there is struggling to deal with the fallout from the conflict. Here are the issues. Continue reading...
From World Cup preparations to Champions League complications, the issues facing football in the region It has been a little over three weeks since the United States and Israel attacked Iran and plunged the Middle East into war. Football there is struggling to deal with the fallout from the conflict. Here are the issues. Continue reading...
Turn Therapeutics ( TTRX ) on Tuesday said it has entered into a growth capital loan facility with Avenue Venture Opportunities Fund II, a fund of Avenue Capital Group, for up to $25 million. The facility includes an initial $7 million tranche funded at closing, with up to an additional $18 million available upon achievement of clinical and corporate milestones. Funds from the initial tranche of t...
Turn Therapeutics ( TTRX ) on Tuesday said it has entered into a growth capital loan facility with Avenue Venture Opportunities Fund II, a fund of Avenue Capital Group, for up to $25 million. The facility includes an initial $7 million tranche funded at closing, with up to an additional $18 million available upon achievement of clinical and corporate milestones. Funds from the initial tranche of the Avenue Capital Group financing are expected to extend Turn Therapeutics’ runway through its Phase 2 atopic dermatitis readout and support preparation for registrational trials for GX-03 as a treatment for moderate-to-severe atopic dermatitis and onychomycosis. The company anticipates that proceeds from the full financing will extend the runway through the end of 2027. Source: Press Release More on Turn Therapeutics Inc. Historical earnings data for Turn Therapeutics Inc. Financial information for Turn Therapeutics Inc.